¿Cómo se compara el ratio PE de VLS con empresas similares?

VLS es un buen valor basado en su ratio Price-To-Earnings (12.5x) comparado con la media de empresas similares (15.2x).

¿Cómo se compara el ratio PE de VLS con el de otras empresas de la industria Global Pharmaceuticals ?

VLS es un buen valor basado en su ratio Price-To-Earnings (12.5x) comparado con la media de la industria Oceanic Pharmaceuticals (16.1x).

¿Cuál es el ratio PE de VLS comparado con su ratio PE justo? Este es el ratio PE esperado teniendo en cuenta las estimaciones de crecimiento de ingresos de la empresa, los márgenes de beneficios y otros factores de riesgo.

Datos insuficientes para calcular el ratio justo Price-To-Earnings de VLS para análisis de valoración.

¿Cuál es el precio justo de VLS si consideramos sus flujos de caja futuros? Para esta estimación utilizamos un modelo de flujo de caja descontado.

VLS (A$2.09) cotiza por debajo de nuestra estimación de [[valor justo]] (A$11.81)

¿Cuál es la estimación de los analistas a 12 meses y, existe una confianza estadística en el precio objetivo de consenso?

Datos insuficientes para mostrar el pronóstico de precios.

Vita Life Sciences (ASX:VLS) - Cotización, noticias y análisis

Resumen de acción VLS

Vita Life Sciences Limited, empresa del sector sanitario, se dedica a la formulación, envasado, distribución y venta de vitaminas y suplementos en Australia, Singapur, Malasia, Tailandia, Vietnam, Indonesia y China. Saber más

Análisis fundamental de VLS
Puntuación del snowflake
Valoración	4/6
Crecimiento futuro	0/6
Rendimiento pasado	4/6
Salud financiera	6/6
Dividendos	4/6

Recompensas

Cotiza un 82.3% por debajo de nuestra estimación de su valor justo

Los beneficios han crecido un 19.8% al año en los últimos 5 años

Análisis de riesgos

No tiene una capitalización de mercado significativa (A$118M)

Historial de dividendos inestable

Los accionistas han sido diluidos en el último año

Competidores de Vita Life Sciences Limited

Vitura Health

ASX:VIT

AU$56.4m

ECS Botanics Holdings

ASX:ECS

AU$22.5m

Neuren Pharmaceuticals

ASX:NEU

AU$1.9b

EZZ Life Science Holdings

ASX:EZZ

AU$127.7m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Vita Life Sciences
Precios históricos de las acciones
Precio actual de la acción	AU$2.09
Máximo en las últimas 52 semanas	AU$2.50
Mínimo de 52 semanas	AU$1.60
Beta	0.49
1Cambio en 1 mes	-3.24%
Variación en 3 meses	-5.43%
Cambio de 1 año	25.90%
3Variación en 3 años	22.94%
Variación en 5 años	239.84%
Variación desde la OPV	1,129.41%

Noticias y actualizaciones recientes

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 23

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

Aug 28

Recent updates

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 23

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

Aug 28

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Mar 22

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Mar 14

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 28

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Dec 20

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

Aug 24

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

May 14

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Mar 18

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Feb 17

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Jan 20

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

Dec 22

Vita Life Sciences Limited's (ASX:VLS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Nov 19

Vita Life Sciences Limited's (ASX:VLS) Prospects Need A Boost To Lift Shares

Jul 14

Rentabilidad de los accionistas

	VLS	AU Pharmaceuticals	Mercado AU
7D	0%	-11.6%	1.4%
1Y	25.9%	43.4%	17.7%

Rentabilidad vs. Industria: Los resultados de VLS fueron inferiores a los de la industria Australian Pharmaceuticals, que obtuvo un rendimiento del 43.4% el año pasado.

Rentabilidad vs. Mercado: VLS superó al mercado Australian, que obtuvo un rendimiento del 17.7% el año pasado.

Volatilidad de los precios

Is VLS's price volatile compared to industry and market?
VLS volatility
VLS Average Weekly Movement	5.1%
Pharmaceuticals Industry Average Movement	10.8%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Precio estable de las acciones: VLS no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de VLS (5%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1947	n/a	Andrew O'Keefe	vitalifesciences.com

Vita Life Sciences Limited, empresa del sector sanitario, se dedica a formular, envasar, distribuir y vender vitaminas y suplementos en Australia, Singapur, Malasia, Tailandia, Vietnam, Indonesia y China. La empresa también ofrece diversos minerales, hierbas y superalimentos. Además, ofrece productos para áreas terapéuticas, como sistema nervioso; nutrición; salud urinaria; control del peso; inmunidad; piel, cabello y uñas; hígado y digestión; fertilidad, embarazo y posparto; control del azúcar en sangre; salud cardiovascular; dolor e inflamación; salud de hombres, mujeres y niños; antioxidantes; huesos, articulaciones y músculos; y salud ocular.

Resumen de fundamentos de Vita Life Sciences Limited

¿Cómo se comparan los beneficios e ingresos de Vita Life Sciences con su capitalización de mercado?
Estadísticas fundamentales de VLS
Capitalización bursátil	AU$118.25m
Beneficios(TTM)	AU$9.39m
Ingresos (TTM)	AU$79.17m

12.5x

Ratio precio-beneficio (PE)

1.5x

Ratio precio-ventas (PS)

¿Está VLS sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de VLS
Ingresos	AU$79.17m
Coste de los ingresos	AU$32.77m
Beneficio bruto	AU$46.41m
Otros gastos	AU$37.01m
Beneficios	AU$9.39m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	0.17
Margen bruto	58.61%
Margen de beneficio neto	11.86%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado VLS a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

4.3%

Rentabilidad actual por dividendo

55%

Ratio de pagos

Resumen de acción VLS

Recompensas

Análisis de riesgos

Competidores de Vita Life Sciences Limited

ASX:VIT

AU$56.4m

ASX:ECS

AU$22.5m

ASX:NEU

AU$1.9b

ASX:EZZ

AU$127.7m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

New minor risk - Shareholder dilution

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Upcoming dividend of AU$0.035 per share

First half 2024 earnings released: EPS: AU$0.078 (vs AU$0.074 in 1H 2023)

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

First half dividend increased to AU$0.035

Recent updates

New minor risk - Shareholder dilution

Vita Life Sciences Limited (ASX:VLS) Looks Inexpensive But Perhaps Not Attractive Enough

Upcoming dividend of AU$0.035 per share

First half 2024 earnings released: EPS: AU$0.078 (vs AU$0.074 in 1H 2023)

Vita Life Sciences (ASX:VLS) Has Announced A Dividend Of A$0.035

First half dividend increased to AU$0.035

Now 22% undervalued

Non-Executive Chairman recently sold AU$654k worth of stock

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Vita Life Sciences Limited (ASX:VLS) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Upcoming dividend of AU$0.06 per share

Vita Life Sciences (ASX:VLS) Has Announced That It Will Be Increasing Its Dividend To A$0.06

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Vita Life Sciences' (ASX:VLS) Shareholders Will Receive A Bigger Dividend Than Last Year

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

New minor risk - Insider selling

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Upcoming dividend of AU$0.03 per share at 3.7% yield

First half 2023 earnings released: EPS: AU$0.074 (vs AU$0.069 in 1H 2022)

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

Investor sentiment improves as stock rises 15%

Upcoming dividend of AU$0.033 per share at 3.9% yield

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

A Look At The Fair Value Of Vita Life Sciences Limited (ASX:VLS)

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Non-Executive Chairman exercised options to buy AU$433k worth of stock.

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Upcoming dividend of AU$0.028 per share

Should You Be Adding Vita Life Sciences (ASX:VLS) To Your Watchlist Today?

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Independent Non-Executive Director Jonathan Tooth has left the company

Investor sentiment improved over the past week

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

If You Like EPS Growth Then Check Out Vita Life Sciences (ASX:VLS) Before It's Too Late

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Did Vita Life Sciences' (ASX:VLS) Share Price Deserve to Gain 83%?

Investor sentiment improved over the past week

Upcoming Dividend of AU$0.028 Per Share

Full year 2020 earnings released: EPS AU$0.12 (vs AU$0.057 in FY 2019)

Vita Life Sciences Limited (ASX:VLS) On An Uptrend: Could Fundamentals Be Driving The Stock?

Vita Life Sciences (ASX:VLS) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Vita Life Sciences (ASX:VLS) Is Well Worth Watching

New 90-day high: AU$1.00